The abstract is read at the publisher; the summary is JClub's.
AAV9-delivered tandem artificial microRNAs targeting HML-2 env in an HML-2 Env transgenic mouse model reduces HML-2 Env expression and ALS-like pathology at 84 days post-injection.
- Why it matters: ALS lacks a cure, and HERV-K HML-2 envelope protein is linked to neurotoxicity and ALS-like symptoms, creating a need for targeted, in vivo silencing strategies.
- What they did: The team screened amiRNAs against the HML-2 env gene in vitro, selected three, and inserted them in tandem into an AAV9 vector; a single intracerebroventricular dose at postnatal Day 1 was tested in thy1-driven HML-2 Env mice.
- The result: Knockdown decreased loss of cortical and spinal motor neurons, alleviated muscle fiber degeneration and fiber-type grouping, and improved motor function, supporting AAV9 tandem amiRNAs for HML-2–linked ALS.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.